Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Click Me!

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 23 July 2004:
Vol. 305. no. 5683, pp. 522 - 525
DOI: 10.1126/science.1095209
Prev | Table of Contents | Next

Reports

A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type b

V. Verez-Bencomo,1* V. Fernández-Santana,1* Eugenio Hardy,2* Maria E. Toledo,3* Maria C. Rodríguez,1 Lazaro Heynngnezz,2 Arlene Rodriguez,2 Alberto Baly,3 Luis Herrera,2 Mabel Izquierdo,2 Annette Villar,1 Yury Valdés,1 Karelia Cosme,2 Mercedes L. Deler,1 Manuel Montane,2 Ernesto Garcia,1 Alexis Ramos,1 Aristides Aguilar,2 Ernesto Medina,2 Gilda Toraño,3 Iván Sosa,2 Ibis Hernandez,3 Raydel Martínez,3 Alexis Muzachio,2 Ania Carmenates,4 Lourdes Costa,2 Félix Cardoso,1 Concepción Campa,5 Manuel Diaz,3 René Roy6*

Glycoconjugate vaccines provide effective prophylaxis against bacterial infections. To date, however, no commercial vaccine has been available in which the key carbohydrate antigens are produced synthetically. We describe the large-scale synthesis, pharmaceutical development, and clinical evaluation of a conjugate vaccine composed of a synthetic capsular polysaccharide antigen of Haemophilus influenzae type b (Hib). The vaccine was evaluated in clinical trials in Cuba and showed long-term protective antibody titers that compared favorably to licensed products prepared with the Hib polysaccharide extracted from bacteria. This demonstrates that access to synthetic complex carbohydrate–based vaccines is feasible and provides a basis for further development of similar approaches for other human pathogens.

1 Center for the Study of Synthetic Antigens, Facultad de Química, Universidad de la Habana, Ciudad Habana, Cuba, 10400.
2 Center for Genetic Engineering and Biotechnology, Apdo 6162, Cubanacan, Playa, Ciudad Habana, Cuba 10600.
3 Institute for Tropical Medicine Pedro Kouri, Autopista Novia del Mediodía, Km 6, La Lisa, Apdo 601, Marianao 13, Ciudad Habana, Cuba 11300.
4 Provincial Center for Hygiene and Epidemiology, Camaguey, Cuba.
5 Finlay Institute, Havana, Cuba 11600.
6 Department of Chemistry, Université du Québec à Montréal, Post Office Box 8888, Succursale Centre-Ville, Montreal, Québec H3C 3P8, Canada.

* To whom correspondence should be addressed. E-mail: vicente{at}fq.uh.cu (V.V.-B.); violeta{at}fq.uh.cu (V.F.-S.); eugenio.hardy{at}cigb.edu.cu (E.H.); mariaeugenia{at}ipk.sld.cu (M.E.T.); roy.rene{at}uqam.ca (R.R.)

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Tetra- and hexavalent mannosides inhibit the pro-apoptotic, antiproliferative and cell surface clustering effects of concanavalin-A: Impact on MT1-MMP functions in marrow-derived mesenchymal stromal cells.
S. Fortier, M. Touaibia, S. Lord-Dufour, J. Galipeau, R. Roy, and B. Annabi (2008)
Glycobiology 18, 195-204
   Abstract »    Full Text »    PDF »
Purification, Cloning, and Expression of an {alpha}/beta-Galactoside {alpha}-2,3-Sialyltransferase from a Luminous Marine Bacterium, Photobacterium phosphoreum.
H. Tsukamoto, Y. Takakura, and T. Yamamoto (2007)
J. Biol. Chem. 282, 29794-29802
   Abstract »    Full Text »    PDF »
Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.
V. Pozsgay, J. Kubler-Kielb, R. Schneerson, and J. B. Robbins (2007)
PNAS 104, 14478-14482
   Abstract »    Full Text »    PDF »
Molecular Cloning, Expression and Properties of an {alpha}/{beta}-Galactoside {alpha}2,3-Sialyltransferase from Vibrio sp. JT-FAJ-16.
Y. Takakura, H. Tsukamoto, and T. Yamamoto (2007)
J. Biochem. 142, 403-412
   Abstract »    Full Text »    PDF »
Health in cuba..
R. S Cooper, J. F Kennelly, and P. Ordunez-Garcia (2006)
Int. J. Epidemiol. 35, 817-824
   Abstract »    Full Text »    PDF »
Characterization of Functional Oligosaccharide Mimics of the Shigella flexneri Serotype 2a O-Antigen: Implications for the Development of a Chemically Defined Glycoconjugate Vaccine.
A. Phalipon, C. Costachel, C. Grandjean, A. Thuizat, C. Guerreiro, M. Tanguy, F. Nato, B. Vulliez-Le Normand, F. Belot, K. Wright, et al. (2006)
J. Immunol. 176, 1686-1694
   Abstract »    Full Text »    PDF »
Toward a Better Understanding of the Basis of the Molecular Mimicry of Polysaccharide Antigens by Peptides: THE EXAMPLE OF SHIGELLA FLEXNERI 5A.
M.-J. Clement, A. Fortune, A. Phalipon, V. Marcel-Peyre, C. Simenel, A. Imberty, M. Delepierre, and L. A. Mulard (2006)
J. Biol. Chem. 281, 2317-2332
   Abstract »    Full Text »    PDF »
Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli.
M. F. Feldman, M. Wacker, M. Hernandez, P. G. Hitchen, C. L. Marolda, M. Kowarik, H. R. Morris, A. Dell, M. A. Valvano, and M. Aebi (2005)
PNAS 102, 3016-3021
   Abstract »    Full Text »    PDF »
Antigenicity and Immunogenicity of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b.
V. Fernandez-Santana, F. Cardoso, A. Rodriguez, T. Carmenate, L. Pena, Y. Valdes, E. Hardy, F. Mawas, L. Heynngnezz, M. C. Rodriguez, et al. (2004)
Infect. Immun. 72, 7115-7123
   Abstract »    Full Text »    PDF »
Synthetic H. influenzae Vaccine Looks Good.
(2004)
Journal Watch Infectious Diseases 2004, 5
   Full Text »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products